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Abstract
Background: Before introduction of reperfusion therapy, fever was frequently observed in
patients with acute myocardial infarction (AMI). Little is known about this symptom during
the widespread use of primary percutaneous coronary intervention (pPCI). The aim of this
study was to assess, whether body temperature is a predictor of impaired left ventricular
systolic function in patients with AMI.
Methods: Our cohort included 171 patients (48 women) aged 57 (51–67) years, admitted due
to the first AMI with ST elevation treated with successful pPCI. Standard body temperature
measurements were performed twice a day. Left ventricular function was assessed by
echocardiography using the wall motion score index (WMSI) and ejection fraction (EF). The
following inflammatory response markers were determined on admission: C-reactive protein,
fibrinogen and white blood cell count.
Results: Within 48 h of observation the median (1st; 3rd quartiles) peak body temperature was
37.0°C (36.7–37.2°C). A temperature above 37.5°C was observed only in 17 (10%) patients.
There was no significant correlation between peak body temperature and any of the determined
inflammatory response markers. WMSI was assessed at 1.3 (1.1–1.6), whereas EF at 56%
(49–62%). There was no significant correlation between the left ventricular function and peak
body temperature or determined markers of inflammation.
Conclusions: In the era of pPCI and aggressive antiplatelet treatment, fever is not a common
symptom associated with uncomplicated AMI and thus not correlated with left ventricular
function and markers of inflammation. (Cardiol J 2012; 19, 4: 369–373)
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Introduction
Recent studies have established a pivotal role
of inflammation in all stages of atherosclerosis —
from plaque initiation to adverse complications of
atherosclerosis, including myocardial infarction [1].
Fever remains the most common and the simplest
noninvasive measure used in inflammatory diseases.
Fever can be defined as an elevation of the
central thermoregulatory set point achieved by dis-
inhibiting thermogenesis. Different pyrogenes (tra-
ditionally viral or bacterial) are recognized by Toll
receptors in macrophages which lead to the release
of interleukin-1b, tumor necrosis factor, and inter-
leukin-6. These endogenous pyrogens stimulate the
production of prostaglandin E2 which alters the set
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point of thermoregulation in the preoptic area of the
hypothalamus [2].
Fever is one of the most frequent signs ob-
served among hospitalized patients [3]. Its presence
is connected with an increase in heart rate, cardiac
work and oxygen consumption, which may be dele-
terious to myocardium affected by infarction. Ani-
mal models have shown that elevated body temper-
ature (BT) was associated with larger infarct size
and more common no-reflow phenomenon [4].
Previous data from 1970s’ showed that the vast
majority of patients with acute myocardial infarc-
tion (AMI) developed fever in the course of AMI.
Another data revealed that early intervention with
b-blockers may lower BT in the acute phase of AMI.
Wide access to interventional therapy and aggres-
sive pharmacological treatment may have changed
this phenomenon and recent studies remain un-
clear. Thus, the aim of our study was to assess if
fever is still common in the course of uncomplicat-
ed AMI and if it reflects the infarct size.
Methods
Study population
We investigated prospectively data of all con-
secutive patients hospitalized in our clinic with the
diagnosis of STEMI treated with primary percuta-
neous coronary intervention (pPCI) within two
years. Patients younger than 18 year-old, with the
history of previous AMI, with known chronic or
acute inflammatory disorder or admitted after 12 h
from symptom onset were excluded from the anal-
ysis. None of the patients was treated with antibi-
otics within the first 48 h of hospitalization.
The study was approved by the local bioethi-
cal committee and all patients gave their informed
consent.
Study protocol
Standard axillary BT measurements were per-
formed twice a day (at 6.00 am and 5.00 pm) during
the period of hospitalization using mercury ther-
mometers. Venous blood samples were drawn on
admission to assay the following inflammatory re-
sponse markers: C-reactive protein (CRP), fibrin-
ogen (FBG) and white blood cell (WBC) count with
peripheral blood smear. All patients within 90 min
from admission had coronary angiography with sub-
sequent primary PCI performed. Standard conco-
mitant therapy (aspirin, thienopyridines, b-blockers,
ACE-inhibitors, statins) was administered in all
eligible patients. We also collected following data:
age, sex, coronary artery disease (CAD) risk factors
(cigarette smoking, hypertension, diabetes mellitus,
hypercholesterolemia), heart rate, systolic blood pres-
sure and signs of heart failure (according to Killip’s
classification) assessed on admission. All patients had
echocardiography performed before discharge from
hospital. Left ventricular (LV) function was assessed
using the wall motion score index (WMSI) and ejec-
tion fraction (EF) by Simpson method.
Statistical analysis
Categorical variables were summarized as fre-
quencies with percentage. Continuous variables
were expressed as medians with interquartile
range. The Shapiro-Wilk test was used to assess
normal distribution of variables. Non-parametric
statistics were used when variables had other than
normal distribution. Correlations were assessed by
using Spearman’s rank correlation coefficient. Dif-
ferences between continuous variables were com-
pared by using the Mann-Whitney U test and
Kruskal-Wallis analysis of variance. All statistical
analyses were performed using STATISTICA 6.0
(StatSoft Inc., USA). A p-value < 0.05 was consid-
ered statistically significant.
Results
Our cohort consisted of 171 patients, aged
57 (51–67) years, 28% of them were women. Pa-
tients were admitted to our hospital within 3 (2–6) h
of symptom onset. Eighty-seven percent of patients
were in Killip class I. Coronary angiography re-
vealed one-vessel disease in half of the group, in
47% of patients right coronary artery was the infarct-
-related artery. Primary PCI using bare metal stents
in 9 out of 10 patients was successful (TIMI grade
flow 3) in 94% of cases. During hospital stay, we
found neither reinfarctions nor deaths in the inves-
tigated group. Other clinical features of the group and
concomitant therapy are presented in Table 1.
Body temperature and inflammatory
response markers
The temperature course within 48 h of obser-
vation is presented on Figure 1. The median peak
BT was 37.0oC (36.7–37.2oC). We observed tempera-
ture above 37.5oC only in 17 (10%) patients (Fig. 2).
WBC count on admission was 10.8 (8.6–12.9) × 103/
/mm3, neutrophiles were dominant in blood smear
— 71.9% (62.8–79.9%). The median CRP level was
2.61 (1.48–5.35) mg/L whereas FBG was 3.7 (2.9–
–4.4) g/L. Killip class, age, sex, the presence of CAD
risk factors, time from symptom onset and admini-
stered therapy didn’t affect BT course. We found
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only weak correlation between peak BT and heart
rate on admission (R = 0.22, p = 0.003). There was
no significant correlation between peak BT and any
of the determined inflammatory response markers.
Left ventricular function
Echocardiography was performed in most cas-
es on the 3rd day of AMI. EF was assessed at 56%
(49–62%) and WMSI at 1.3 (1.1–1.6). There was no
significant correlation between LV function and peak
BT (Figs. 3, 4) or the determined markers of inflam-
mation. EF was statistically significant correlated
with heart rate on admission (R = –0.20; p = 0.008)
and Killip class (R = –0.15; p = 0.042), whereas
WMSI with time from symptom onset (R = 0.21;
p = 0.006), heart rate (R = 0.17; p = 0.030), Killip
class (R = 0.17; p = 0.028) and systolic blood pres-
sure measured on admission (R = –0.18; p = 0.016).
Discussion
In our well treated cohort we evaluated BT
course in addition to markers of inflammation and
Table 1. Patient (n = 171) characteristics, coro-
nary angiography findings and concomitant
treatment.
Age [years] 57 (51–67)
Women 48 (28%)
Heart rate [bpm] 75 (65–87)
Blood pressure [mm Hg]:
Systolic 130 (120–140)
Diastolic 80 (70–90)
Anterior AMI 59 (35%)
Time from symptom onset [h] 3 (2–6)
Killip class:
I 150 (87%)
II 17 (10%)
III 3 (2%)
IV 1 (1%)
Hypertension 117 (68%)
Diabetes 26 (15%)
Hyperlipidemia 78 (46%)
Family history of CAD 59 (35%)
Smoking status:
None 42 (25%)
Current 94 (55%)
Serum creatinine [mg/dL] 0.9 (0.8–1.0)
Results of coronarography:
One-vessel disease 91 (53%)
Two-vessel disease 55 (32%)
Three-vessel disease 24 (14%)
Infarct-related artery:
LAD 60 (35%)
Cx 25 (15%)
RCA 81 (47%)
Stent 158 (92%)
TIMI grade flow 3 160 (94%)
Concomitant therapy:
Aspirin 169 (99%)
Thienopyridines 161 (94%)
GP IIb/IIIa blocker 114 (66%)
Statins 170 (99%)
Beta-blockers 155 (91%)
ACE inhibitors 155 (91%)
ACE — angiotensin-converting enzyme; AMI — acute myocardial
infarction; CAD — coronary artery disease; Cx — circumflex artery;
GP — glycoprotein; LAD — left anterior descending artery;
RCA — right coronary artery
Figure 1. The temperature course within the first 48 h of
hospitalization. Median, interquartile range, minimal
and maximal values (oC).
Figure 2. Distribution of peak body temperature (BT)
within 48 h of hospitalization.
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its relation to LV function assessed by EF and wall
motion score index. We found that only 10% of pa-
tients developed BT higher than 37.5oC. Regarding
age, sex, risk factors and heart failure signs there
was no difference in temperature course. Finally,
peak BT was not correlated with EF, WMSI and
inflammatory markers.
Lofmark et al. [5] in 1970s’, studied data of 192
consecutive patients with AMI. BT, measured rec-
tally, reached its maximum between day 2 and 5.
Only 11% of patients did not develop fever during
the myocardial course. BT rarely reached 38.2oC
in the first morning and maximal temperature did
not exceed 39oC during hospital stay. Prolonged
fever duration (longer than 8 days) was connected
with significantly higher SGOT concentrations.
Almost 10 years later, Risoe et al. [6] studied
data of 65 patients admitted with AMI within 4 h of
symptom onset. In this prospective study, 33 pa-
tients were randomized to timolol iv treatment and
32 to placebo group. BT was measured rectally
twice a day. Temperature rose higher and the fe-
ver lasted longer in the placebo group (5.5 vs 4.5
days with BT > 37.5oC measured in the morning
and 5 vs 4 days for BT > 37.7oC measured in the
evening). Both the mean and the maximal temper-
atures were significantly lower in the timolol group.
The maximal and mean temperatures were also sig-
nificantly correlated with infarct size and ischemic
area (assessed by cumulative creatine kinase [CK]
release, QRS vector difference and initial ST vector
magnitude) in the whole group and in the placebo
group. The authors suggested that the fever response
after MI is initiated by necrotic myocardium, and
reduction of infarct size due to early b-blocker the-
rapy may explain the reduction of the pyrexial
response after AMI.
In another study, Ranjadayalan et al. [7] evalu-
ated the effects of thrombolytic therapy on temper-
ature responses in AMI. Eighty-five out of 156 pa-
tients received thrombolytic therapy, BT measure-
ments were gathered through the first 72 h of
hospitalization. Thrombolysis was associated with
significant reductions in both mean (36.8 ± 0.6 vs
37.0 ± 0.6oC, p < 0.001) and peak temperature
(37.6 ± 0.5 vs 37.9 ± 0.5oC, p < 0.005). Patients
who did not develop Q-wave MI had lower mean and
peak BT (36.7 ± 0.5 vs 36.9 ± 0.6oC, p < 0.001 and
37.5 ± 0.5 vs 37.8 ± 0.5oC, p < 0.02 respectively)
than in the Q-wave infarction. BT were significant-
ly correlated with peak CK release (r = 0.31 for
mean and 0.25 for peak BT, p < 0.005). The authors
concluded that the altered fever response after AMI
is caused by reduction of infarct size.
BT was also evaluated in large clinical trials.
Infarct size assessed by measuring CK-MB area
under the curve and clinical outcomes were corre-
lated with WBC count and initial BT in 1800 patients
with STEMI treated with primary angioplasty — the
COMplement inhibition in Myocardial infarction
treated with Angioplasty (COMMA) trial (n = 960)
or with fibrynolytics — the COMPlement inhibition
in myocardial infarction treated with thromboLYt-
ics (COMPLY) trial (n = 934). Increasing initial BT
was associated with a longer time from symptom
onset but not related to infarct size, heart failure
and mortality. Patients with increased initial WBC
count had greater infarct size and higher six-month
mortality. Patients with increasing WBC count dur-
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Figure 3. Correlation between peak body temperature
(BT) and left ventricle ejection fraction (EF).
Figure 4. Correlation between peak body temperature
(BT) and wall motion score index (WMSI).
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ing the first 24 h of observation had higher rates
of shock, congestive heart failure, and death at
90 days. Baseline temperature and WBC count were
not correlated with each other. The authors con-
cluded that there was a direct association between
inflammatory state and infarct size and adverse clin-
ical outcomes. But the limitation of this study is lack
of analysis of BT changes. Echocardiographic find-
ings could be also useful [8].
Ben-Dor et al. [9] conducted an evaluation simi-
lar to our cohort of patients with STEMI. All 
40 patients underwent urgent coronary angiogra-
phy with subsequent successful PCI and optimal
drug treatment. BT was measured rectally, which
can explain slightly higher values of median tem-
peratures — 37.4oC (36.9–37.6oC) vs 37.0oC (36.7–
–37.2oC) in our group. The median WMSI was 1.56
(1.23–1.88) which is slightly higher value in compari-
son to our results. They found significant correlation
between peak BT and peak CK, WMSI (r = 0.41) and
hs-CRP levels (assessed 24 h after admission, r =
= 0.41), but not with WBC count. In multivariate
analysis only CRP levels were independently relat-
ed to LV function assessed by WMSI. Authors con-
cluded that BT was related to infarct size, and unre-
lated to nonspecific inflammatory response.
Naito et al. [10] evaluated data of 156 patients
with AMI treated with PCI (88%) and thromboly-
sis (12%) but with relatively low usage of statins
(31%). Axillary BT was measured every 6 h for
a week. Mean peak BT was 37.6 ± 0.6oC after 38 ±
± 22 h from symptom onset. Peak BT quartile was
associated with significantly higher peak CRP le-
vel, but not with peak WBC count. EF assessed by
echocardiography did not significantly correlate
with peak BT, but ventriculography performed
2 weeks after AMI revealed significant association
between peak BT and LVEF. Patients in the high-
est quartile of peak BT had more often heart fail-
ure, malignant ventricular arrhythmias, cardiac rup-
ture or cardiac death during hospitalization. What
is more, higher peak BT quartile was an indepen-
dent determinant of readmission for heart failure.
Authors suggested the existence of a relationship
between systemic inflammatory response and
postinfarction LV remodeling.
Limitations of the study
Relatively small group of patients with elevat-
ed BT is the most important limitation of this study.
Axillary BT measurement may not be an accurate
method — especially in critically ill patients. Re-
peated assays of inflammatory markers in addition
to troponin levels could be useful as well.
Conclusions
In the era of pPCI and aggressive antiplatelet
treatment, fever is not a common symptom associ-
ated with AMI and is not correlated with LV func-
tion and standard markers of inflammation.
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